Surmodics, Inc.
SRDX · NASDAQ
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | 3.11 | 0.02 | 0.66 |
| FCF Yield | -0.59% | 1.69% | -4.87% | 1.19% |
| EV / EBITDA | 115.48 | 29.18 | -34.26 | 50.97 |
| Quality | ||||
| ROIC | -5.46% | -1.96% | -19.52% | 2.55% |
| Gross Margin | 73.81% | 46.03% | 29.01% | 39.21% |
| Cash Conversion Ratio | -0.02 | -6.85 | 0.63 | 3.63 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.05% | 8.04% | 1.76% | 1.66% |
| Free Cash Flow Growth | -142.71% | 136.89% | -326.05% | -11.89% |
| Safety | ||||
| Net Debt / EBITDA | -0.61 | -0.54 | 0.34 | -1.19 |
| Interest Coverage | -1.59 | 1.48 | -36.95 | 21.62 |
| Efficiency | ||||
| Inventory Turnover | 2.18 | 4.82 | 6.00 | 9.45 |
| Cash Conversion Cycle | 204.22 | 126.22 | 133.04 | 107.97 |